Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.

Autor: Malinverni C; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy., Bernardelli A; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy., Glimelius I; Department of Immunology, Genetics and Pathology, Cancer Precision Medicine, Uppsala University, Uppsala, Sweden., Mirandola M; Epidemiology Unit, Division of Infectious Diseases, Department of Medicine, World Health Organization Collaborating Centre for Sexual Health and Vulnerable Populations, Verona University Hospital, Verona, Italy.; School of Health Sciences, University of Brighton, Brighton, United Kingdom., Smedby KE; Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Solna, Sweden.; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden., Tisi MC; Department of Hematology and Cell Therapy, San Bortolo Hospital, Vicenza, Italy., Giné E; Department of Hematology, Hospital Clinic of Barcelona, Barcelona, Spain., Albertsson-Lindblad A; Department of Oncology, Skane University Hospital, Lund, Sweden., Marin-Niebla A; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain., Di Rocco A; Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Moita F; Department of Hematology, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal., Sciarra R; Division of Hematology, Fondazione IRCSS Policlinico San Matteo, Pavia, Italy., Bašić-Kinda S; Division of Hematology, University Hospital Centre, Zagreb, Croatia., Hess G; Department of Hematology, Oncology, and Pneumology, Comprehensive Cancer Center, Johannes Gutenberg University, Mainz, Germany., Ohler A; Department of Hematology, Oncology, and Pneumology, Comprehensive Cancer Center, Johannes Gutenberg University, Mainz, Germany., Eskelund CW; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Re A; Division of Hematology, Spedali Civili di Brescia, Brescia, Italy., Ferrarini I; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy., Kolstad A; Department of Oncology, Sykehuset Innlandet, Lillehammer, Norway., Räty R; Department of Hematology, Helsinki University Hospital, Helsinki, Finland., Quaglia FM; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy., Eyre TA; Department of Clinical Hematology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, United Kingdom., Scapinello G; Division of Hematology and Clinical Immunology, Department of Medicine, University of Padua, Padua, Italy., Stefani PM; Division of Hematology, Treviso Regional Hospital, Treviso, Italy., Morello L; Department of Medical Oncology and Hematology, Humanitas Clinical and Research Center, Milan, Italy., Nassi L; Division of Hematology, Careggi Hospital and University of Florence, Florence, Italy., Hohaus S; Department of Radiological and Hematological Sciences, Catholic University of the Sacred Heart, Rome, Italy., Ragaini S; Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Turin, Turin, Italy., Zilioli VR; Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bruna R; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont Amedeo Avogadro, Novara, Italy., Cocito F; Division of Hematology, San Gerardo Hospital, Monza, Italy., Arcari A; Division of Hematology, Ospedale Guglielmo da Saliceto, Piacenza, Italy., Jerkeman M; Department of Oncology, Lund University Hospital, Lund, Sweden., Visco C; Department of Engineering for Innovation Medicine, Section of Hematology, University of Verona, Verona, Italy.

Publikováno v: Blood [Blood] 2024 Aug 29; Vol. 144 (9), pp. 1001-1009.

Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas.

Autor: Leivonen SK; Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki., Friman T; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki., Autio M; Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki., Vaittinen S; Department of Pathology, Turku University Hospital, University of Turku, Turku., Jensen AW; Department of Hematology, Aarhus University Hospital, Aarhus., D'Amore F; Department of Hematology, Aarhus University Hospital, Aarhus., Hamilton-Dutoit SJ; Institute of Pathology, Aarhus University Hospital, Aarhus., Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway., Beiske K; Department of Pathology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Kovanen PE; Department of Pathology, University of Helsinki, and HUSLAB, Helsinki University Hospital, Helsinki., Räty R; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki., Leppä S; Applied Tumor Genomics Research Program, Medical Faculty, University of Helsinki, Helsinki, Finland; Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland; iCAN Digital Precision Cancer Medicine Flagship, Helsinki. sirpa.leppa@helsinki.fi.

Publikováno v: Haematologica [Haematologica] 2023 Nov 01; Vol. 108 (11), pp. 3044-3057. Date of Electronic Publication: 2023 Nov 01.

Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL.

Autor: Husby S; Department of Hematology, Rigshospitalet, Copenhagen, Denmark. simon.husby.01@regionh.dk.; Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark. simon.husby.01@regionh.dk., Bæch-Laursen C; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark., Eskelund CW; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark., Favero F; Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark.; Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark., Jespersen JS; Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark.; Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark., Hutchings M; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Pedersen LB; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Weischenfeldt J; Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark.; Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark., Räty R; Department of Hematology, Helsinki University Central Hospital, Helsinki, Finland., Larsen TS; Department of Hematology, Odense University Hospital, Odense, Denmark.; Centre for Cellular Immunotherapy of Haematological Cancer Odense (CITCO), Odense University Hospital, Odense, Denmark., Kolstad A; Department of Oncology, Innlandet Hospital, Lillehammer, Norway., Jerkeman M; Department of Oncology, Lund University Hospital, Lund, Sweden., Grønbæk K; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: Leukemia [Leukemia] 2022 Dec; Vol. 36 (12), pp. 2912-2916. Date of Electronic Publication: 2022 Oct 23.

Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score.

Autor: Salim R; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, BRIC, University of Copenhagen, Copenhagen, Denmark., Husby S; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, BRIC, University of Copenhagen, Copenhagen, Denmark., Winther Eskelund C; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Scott DW; Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, Canada., Holte H; Department of Oncology, Oslo University Hospital, Norway and KG Jebsen Centre for B-cell malignancies, Oslo, Norway., Kolstad A; Department of Oncology, Division Gjøvik-Lillehammer, Innlandet Hospital Trust, Innlandet, Norway., Räty R; Department of Hematology, Helsinki University Hospital, Helsinki, Finland., Ek S; Department of Immunotechnology, Lund University, Lund, Sweden., Jerkeman M; Department of Oncology, Lund University, Lund, Sweden., Geisler C; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Sommer Kristensen L; Department of Biomedicine, Aarhus University, Aarhus, Denmark., Dahl M; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, BRIC, University of Copenhagen, Copenhagen, Denmark., Grønbæk K; Department of Hematology, Rigshospitalet, Copenhagen, Denmark.; Biotech Research and Innovation Centre, BRIC, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health science, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2023 Jul-Aug; Vol. 64 (8), pp. 1414-1423. Date of Electronic Publication: 2023 Jun 01.

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.

Autor: Kolonen A; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Sinisalo M; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Huhtala H; Faculty of Social Sciences, Tampere University, Tampere, Finland., Rimpiläinen J; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Rintala H; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Sankelo M; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Koivunen E; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Silvennoinen R; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland., Räty R; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland., Ruutu T; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland., Volin L; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland., Porkka K; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland., Jantunen E; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Nousiainen T; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Kuittinen T; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Penttilä K; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Pyörälä M; Department of Medicine, Kuopio University Hospital, Kuopio, Finland., Säily M; Department of Medicine, Oulu University Hospital, Oulu, Finland., Koistinen P; Department of Medicine, Oulu University Hospital, Oulu, Finland., Kauppila M; Stem Cell Transplantation Unit, Turku University Hospital, Turku, Finland., Itälä-Remes M; Stem Cell Transplantation Unit, Turku University Hospital, Turku, Finland., Ollikainen H; Department of Medicine, Satakunta Central Hospital, Pori, Finland., Rauhala A; The Faculty of Education and Welfare Studies, Department of Health Sciences, Åbo Akademi University, Vaasa, Finland.; Client and Patient Safety Center, Vaasa Central Hospital, Vaasa, Finland., Kairisto V; Laboratory of Molecular Haematology and Pathology, Turku University Central Hospital, Turku, Finland., Pelliniemi TT; Department of Clinical Chemistry, University of Turku, Finland and Fimlab Laboratories Ltd, Tampere, Finland., Elonen E; Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland.

Publikováno v: European journal of haematology [Eur J Haematol] 2022 Sep; Vol. 109 (3), pp. 257-270. Date of Electronic Publication: 2022 Jun 14.